本帖最后由 老马 于 2012-1-13 21:20 编辑 * X% x$ [( A4 M2 R- V* N% q
! B! n, s$ e' t/ C6 _爱必妥和阿瓦斯丁的比较
" \; O. h9 v( |; P/ e7 c
& W5 J2 I$ m U( K" H: ^" {5 \http://cancergrace.org/lung/2008/08/30/bms099-os-neg/. w' ^% O) G y# b+ L
8 c9 A# q8 @! K2 A% {9 Q6 X
: m% [/ a# Z) D; ]http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ I- o f, k7 H" o! s==================================================" K- J. M. }3 Q. z% O1 _- }
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, _) p# l: c o3 X9 W4 u8 c1 t5 d- j, YPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" S, r) i2 h/ u2 [: uResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. {( W3 ~5 g/ T& B# c0 R9 |. i
|